These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 455611)

  • 1. Platelet kinetic studies in patients with hyperlipoproteinemia: effects of clofibrate therapy.
    Harker LA; Hazzard W
    Circulation; 1979 Sep; 60(3):492-6. PubMed ID: 455611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease.
    Steele P; Battock D; Genton E
    Circulation; 1975 Sep; 52(3):473-6. PubMed ID: 1157247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia.
    Carvalho AC; Colman RW; Lees RS
    Circulation; 1974 Sep; 50(3):570-4. PubMed ID: 4369866
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of clofibrate on intravascular coagulation in hyperlipoproteinemia.
    Carvalho AC; Lees RS; Vaillancourt RA; Colman RW
    Circulation; 1977 Jul; 56(1):114-8. PubMed ID: 301067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral anticoagulants and platelet function in hypolipemic therapy using a new clofibrate analog (BM 15.075) (author's transl)].
    Zimmermann R; Hoffrichter A; Walter E; Ehlers W; Andrassy K; Lang PD; Schlierf G; Weber E; Barth P
    Dtsch Med Wochenschr; 1977 Apr; 102(14):509-12. PubMed ID: 852404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
    MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W; Kremer GJ; Müller D
    MMW Munch Med Wochenschr; 1975 Oct; 117(44):1783-6. PubMed ID: 171564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet function in hyperbetalipoproteinemia.
    Colman RW
    Thromb Haemost; 1978 Apr; 39(2):284-93. PubMed ID: 580982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR; Klemens UH; Vollmar LJ; Lang PD
    Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
    Weisweiler P; Schwandt P
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():398-401. PubMed ID: 206058
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
    Koschinsky T; Lenhard P; Gries FA; Vogelberg KH; Wolfram G; Lang PD; Vollmar J
    Med Klin; 1977 Sep; 72(38):1537-43. PubMed ID: 904549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and in vivo distribution of in-111-labelled platelets and platelet function in familial hypercholesterolaemia.
    Wessels P; Heyns AD; Esterhuysen AJ; Badenhorst PN; Lötter MG; Pieters H; Kotzè HF
    Thromb Haemost; 1987 Oct; 58(3):811-6. PubMed ID: 3433247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings.
    Fletcher A; Alkjaersig N; Schonfeld G; Witztum J
    Arteriosclerosis; 1981; 1(3):202-9. PubMed ID: 7295193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should hyperlipoproteinemia be treated in patients with coronary artery disease?
    Rider AK
    JAMA; 1975 Jul; 233(3):275-7. PubMed ID: 168412
    [No Abstract]   [Full Text] [Related]  

  • 15. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
    Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
    Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
    Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultracentrifugal demonstration of floating beta lipoproteins in type 3 hyperlipoproteinemia. Diagnostic value.
    Aubry F; Lapierre YL; Noël C; Davignon J
    Ann Intern Med; 1971 Aug; 75(2):231-7. PubMed ID: 5558651
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination of clofibrate and inositol nicotinate (author's transl)].
    Wilke H; Frahm H
    Dtsch Med Wochenschr; 1976 Mar; 101(11):401-5. PubMed ID: 1253701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical effects and tolerance of etofylline clofibrate].
    Ziegler WJ; Metz G; Specker M
    Arzneimittelforschung; 1980; 30(11b):2053-8. PubMed ID: 7194059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
    Szapary L; Horvath B; Marton Z; Alexy T; Kesmarky G; Habon T; Szots M; Koltai K; Juricskay I; Czopf J; Toth K
    CNS Drugs; 2004; 18(3):165-72. PubMed ID: 14871160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.